Skip to main content

Talk Bio

Search This Blog

AbbVie scores dual EU approvals for Rinvoq in vitiligo, alopecia

on July 30, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

AbbVie has secured final European Commission approval for Rinvoq (upadacitinib) for adults and adolescents 12 years and older with severe alopecia areata and non‑segmental vitiligo.

In the EU, Rinvoq is now indicated for both severe alopecia areata and non‑segmental vitiligo, expanding its use beyond its existing inflammatory‑disease indications.

These approvals follow positive opinions from the European Medicines Agency’s CHMP in June 2026, making Rinvoq the first systemic treatment available in the EU for non‑segmental vitiligo.

Sources:

AbbVie Announces European Commission Approval of ...

AbbVie Gets Europe OK for Rinvoq in Vitiligo, Alopecia ...

ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases

Rinvoq - opinion on variation to marketing authorisation - EMA

AbbVie says EU CHMP backs Rinvoq approval for non- ...

AbbVie Gets CHMP Backing for Rinvoq in Vitiligo, Alopecia Areata

Abbvie Receives Positive Chmp Opinion for Upadacitinib for ...

AbbVie’s RINVOQ moves closer to Europe’s first vitiligo pill

EU approves RINVOQ for severe alopecia areata, ... | Pluang

AbbVie wins EU clearance for Rinvoq as first systemic treatment for non-segmental vitiligo (ABBV:NYSE)

AbbVie (ABBV) Wins Backing For Two RINVOQ Skin Disease Uses In Europe

AbbVie's Rinvoq bags two new EU approvals

AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis

AbbVie Announces European Commission Approval of ...

AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU

AbbVie Adolescent (age group) Adult Alopecia Approved CHMP EU European Commission approval older Opinions Positive Rinvoq Severe (severity modifier) systemic treatment upadacitinib Vitiligo

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC